Pasar al contenido principal

PROTEOMICA EN SISTEMAS DE FOSFORILACION DE AZUCARES EN BACTERIAS: UNA APROXIMACION CRISTALOGRAFICA Y ESPECTROSCOPICA.

SAF2008-05742-C02-01

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2008
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Discovery of specific flavodoxin inhibitors as potential therapeutic agents against Helicobacter pylori infection

  • Cremades, Nunilo
  • Velázquez-Campoy, Adrián
  • Martínez-Júlvez, Marta
  • Neira, José L.
  • Pérez-Dorado, Inmaculada
  • Hermoso, Juan A.
  • Jiménez Sierra, M. Pilar
  • Lanas, Ángel
  • Hoffman, Paul S.
  • Sancho, Javier
Helicobacter pylori establishes life-long infections in the gastric mucosa of over 1 billion people worldwide. In many cases, without specific antimicrobial intervention, H. pylori infected individuals will develop type B gastritis, chronic peptic ulcers and, more rarely, gastric neoplasias. Conventional antimicrobial therapy has been complicated by dramatic increases in resistance to macrolides, metronidazole and fluoroquinolones. Here, we report the development of novel therapeutics that specifically target the unique flavodoxin component of an essential metabolic pathway of H. pylori. With the use of high-throughput screening methodology, we have tested 10,000 chemicals and have identified 29 compounds that bind flavodoxin, four of which interrupted in vitro electron transfer to flavodoxin physiological partners. Three of these compounds are bactericidal and promisingly selective for H. pylori. The minimal inhibitory concentrations of two of them are 10 times lower than their minimal cytotoxic concentrations for HeLa cells. Importantly, neither of the four inhibitors is toxic for mice after administration of 1–10 mg kg−1 doses twice a day for 5 days. Enzymatic, thermodynamic and structural characterization of the inhibitor–flavodoxin complexes suggests these compounds could act by modifying the redox potentials of flavodoxin. These newly discovered inhibitors represent promising selective leads against the different diseases associated to H. pylori infection., We acknowledge financial support from grants BFU2007-61476/BMC, CTQ2005-00360, SAF2008-05742-C02-01 (to J.L.N.) and CSD-2008-00005 (to J.L.N.) from Spanish Ministerio de Educación y Ciencia (MEC), grant PI078/08 from Gobierno de Aragón (Spain), grant 2008/0670 from Genoma España, grant FIPSE (Exp 36557/06) to J.L.N., and NIH grants R01DK073823 and U01AI075520 to P.S.H. N.C. and I.P.-D. were supported by FPU and I3P-CSIC fellowships (Spain), respectively.